

Biosketches

Devon Adams, MPH

Devon Adams is a Senior Analyst, Policy and Legislative Support at the American Cancer Society Cancer Action Network. He works on issues in the Emerging Science portfolio which includes clinical trials, research and development of cancer drugs, and cancer biomarker testing. He has experience in health policy, government relations, and clinical care having practiced as a registered nurse.

Dara Aisner, MD, PhD

Dr. Dara Aisner is a board-certified certified Anatomic and Molecular Genetic Pathologist and is also board certified in Clinical Informatics. She is an Associate Professor of Pathology at the University of Colorado School of Medicine in Denver, Colorado and a member of the University of Colorado Comprehensive Cancer Center.

Dr. Aisner is the director of the Colorado Molecular Correlates Laboratory within the Department of Pathology, which focuses on testing in precision medicine. She is a member of numerous oncology pathology and guidelines committees including the CAP/AMP/IASLC Guidelines for Biomarker Testing in Non-Small Cell Lung Cancer and the NCCN non-small cell lung cancer panel, and the College of American Pathologists Genomic Medicine Resource Committee, among others. She has been a past member of the Association for Molecular Pathology Economic Affairs Committee.

Bo Aldigé

Carolyn R. (“Bo”) Aldigé is Founder and CEO of the Prevent Cancer Foundation®, a national non-profit organization she started in 1985 in memory of her father. Today, the Foundation® is nationally recognized as a leader in the fight

against cancer through prevention and early detection and receives the highest ratings from all “charity watchdogs”.

Ms. Aldigé serves on the External Advisory Board of MD Anderson Cancer Center, the boards of directors of Friends of Cancer Research and the Intercultural Cancer Council, the Board of Overseers of the Vanderbilt Ingram Cancer Center, the advisory board of Project ECHO, the External Advisory Board of the Center for Thoracic Oncology of the Mount Sinai Health System, and the advisory board of Stand Up to Cancer. She is chairman of Global Action for Cancer Patients and vice-chairman of the Global Lung Cancer Coalition.

She has been honored for public service by the National Cancer Institute and numerous NGOs, including AACR and ASCO.

Naveen Babbar, PhD

Naveen Babbar, PhD is Global Precision Medicine Leader (Exec Dir), Precision Medicine at Novartis Oncology. There he leads the strategy, design and delivery of precision medicine strategy supporting Global Program Teams (GPT) including biomarker discovery, development of assays and companion diagnostics to support patient selection and stratification ensuring regulatory approval, technical market access and optimized commercial value.

Dr. Babbar received his PhD in Biochemistry, Molecular & Cellular Biology from the University of Arizona.

Brett Bade, MD

Brett Bade is a pulmonologist at Yale University’s School of Medicine and the West Haven Veterans Affairs Hospital, and his career

Biosketches

goal is to advance lung cancer survivorship care via optimizing quality of life and functional independence. As a clinician caring for patients with lung cancer and chronic lung disease, it is clear to him that quality of life, symptom burden, and overall outcome are related to physical activity level. Further, implementation of treatments to address physical inactivity in lung cancer are poorly understood and under-utilized. To address these limitations, his preliminary work has focused on the feasibility and potential benefit of home-based physical activity regimens. It is his belief that lung cancer survivorship should assess a patient's symptoms, quality of life, physical function, and baseline activity level at the time of diagnosis and manage these issues concurrently with cancer-directed therapy. Recognizing that an individualized approach is most likely to be effective, Dr. Bade's long-term goal is to develop "targeted" strategies for the type and timing of physical activity interventions for lung cancer survivors.

Upal Basu Roy, PhD, MPH

Upal Basu Roy is Vice President of Research at LUNGeVity Foundation, the pre-eminent lung cancer patient advocacy group in the United States. In this capacity, he directs both the Translational Science Research Program and the Patient-Focused Research Center (Patient FoRCe). Within the Translational Science Research Program, Upal guides the award administration and peer review of lung cancer translational research grants, as well as the monitoring and evaluation of research projects that focus on improving outcomes via early detection and improved treatment options. Within Patient FoRCe, he designs, implements, and manages all phases of research studies that seek to understand

the lung cancer patient experience and identify unmet needs in education and access to care. Specifically, he manages protocol development to project execution to recommendations on how to incorporate Patient FoRCe research study findings into clinical practice. Upal has spearheaded several multi-stakeholder research projects that aim to increase access to lung cancer screening, biomarker testing, and clinical trials for lung cancer patients.

Upal firmly believes that lung cancer advocacy is a continuum that ranges from activities focused on individual patients to those spanning communities, organizations, and policy makers. As a patient research advocate, he works with national organizations such as the United States Food and Drug Administration, the National Cancer Institute, other patient advocacy groups, and pharma partners on policy initiatives to make clinical trials more streamlined and patient-centric.

Upal has over 10 years of translational cancer research experience in the laboratory. He has a PhD in Cancer Biology and an MPH in Global Health Policy and Management. Upal is a published author and serves as peer reviewer for translational science and public health journals.

Joshua Bergren

Joshua Bergren is Director of Patient Advocacy at Pfizer Oncology for Renal, Lung, and Immuno-Oncology. Josh has 13 years' experience at Pfizer, including helping to launch early targeted therapies for lung cancer. Josh

Biosketches

has an extensive background in patient access and reimbursement as well financial advocacy. Pfizer is committed to advancing precision medicine and access to biomarker testing for all appropriate patients, and Josh drives that effort in lung cancer, in partnership with patient advocates and professional societies

David Bernstein, PhD

David Bernstein is the Senior Director of Science and Strategy for Stand Up To Cancer and is based in New York. David oversees the development of new scientific projects and grants at SU2C, as well as the translation of grantees' achievements for lay audiences. SU2C grants generally support milestone-driven, multi-investigator, multi-institutional collaborative research projects that span many disciplines within and beyond the biological sciences and medicine.

Following a Ph.D. in biochemistry from the University of Wisconsin-Madison, David was awarded a AAAS Congressional Fellowship and served on the Senate Health, Education, Labor and Pensions Committee staff. One of his main focuses during this time were public health issues related community-level preparation and response to infectious disease and bioterrorism. After the Fellowship, David was the Senior Science Policy Analyst at the American Association for Cancer Research (AACR), the first full-time member of their government relations department, and contributed to SU2C scientific reviews in addition to managing Congressional and Executive branch policy issues impacting cancer research. David then became Associate Director of Research Policy at the American Society of Clinical Oncology (ASCO). There he managed FDA collaborations, developed the Society's input on regulatory policy, and coauthored papers on clinical trial design.

Anna Berry, MD

Dr. Anna Berry is the Vice President for Molecular Pathology and Genomics at Syapse, where she works in partnership with Syapse's functional leaders to support product and service development, serves as a subject matter expert to Syapse's customers, participates in joint-authored research and publications, and advances Syapse's thought leadership efforts in the area of real-world evidence. Prior to her recent move to Syapse, she served for 6 years as the Deputy Director for Molecular Pathology and Genomics, and as the Scientific Director for the Personalized Medicine Program at the Swedish Cancer Institute in Seattle, and concurrently served as Director of Genomics Programs at CellNetix Pathology and Laboratories. She has also served on the faculty at the University of California San Francisco for 9 years, where she rose to the rank of Associate Professor. While at UCSF, she was the inaugural Director of Molecular Pathology, and the inaugural Molecular Genetic Pathology Fellowship Director, and served as an attending physician in the Fine Needle Aspiration Clinic. Dr. Berry has focused professionally on genomics education and personalized medicine. In these roles, she has given numerous presentations, nationally and internationally, and has served on multiple task forces and committees for several professional organizations and coalitions, spanning Pathology and Oncology focused efforts. She has also been published in these areas of study. Dr. Berry completed her undergraduate studies from the University of Wyoming and earned her medical degree from the University of Nebraska Medical Center. She has board certifications in Anatomic and Clinical Pathology, Cytopathology, and Molecular Genetic Pathology.

Biosketches

Win Boerckel, MSW, MBA, LCSW-R

Mr. Winfield Boerckel, “Win” serves as CancerCare’s Long Island Director of Social Service and is charged with directing clinical services delivered to Long Island residents dealing with a diagnosis of cancer or providing care to a loved one with cancer. In addition, he coordinates CancerCare’s National Lung Cancer Program, and maintains clinical responsibility for developing and implementing supportive activities and systems for lung cancer patients and their caregivers; he also facilitates virtual support groups for cancer caregivers and lung cancer patients on Long Island.

Mr. Boerckel serves on the professional advisory boards for the websites: lungcancer.org, and the ASCO website, www.cancer.net. In addition, he had served on the editorial advisory board of CURE Magazine. He is also CancerCare’s delegate to the Global Lung Cancer Coalition, and, participates as Treasurer on that organization’s Steering Committee. He represents CancerCare at LungCAN. He is a recipient of the Lung Cancer Alliance’s first annual Lung Cancer Support Group Award. He participates in the American Cancer Society’s National Lung Cancer Roundtable as a member of the Shared Decision Making Task Group and has presented on lung cancer patient psychosocial needs at workshops both in the United States and Europe.

Durado Brooks, MD, MPH

Dr. Brooks has worked for the American Cancer Society’s national headquarters since 2000. He oversees the design, implementation and evaluation of cancer prevention and early detection programs at the national, state and local levels to increase access to high quality prevention and screening, and to decrease cancer-related disparities.

Dr. Brooks practiced primary care medicine for fifteen years at safety net facilities in Dayton, Ohio and in his current hometown of Dallas, Texas. His interest in policy solutions to health disparities led him to leave clinical practice to complete the Commonwealth Fund Fellowship in Minority Health Policy and earn an MPH degree from the Harvard School of Public Health.

Dr. Brooks was the 2015 recipient of the Prevent Cancer Foundation’s Laurel Award for National Leadership in Cancer Prevention and Early Detection.

Suanna Bruinooge, MPH

Suanna Bruinooge, MPH, is the Division Director of Research Strategy and Operations in ASCO’s Center for Research and Analytics (CENTRA). CENTRA generates, integrates, analyzes, and shares oncology data to foster innovation in research and patient care and help develop and evaluate ASCO’s policy positions. CENTRA develops and implements ASCO’s research priorities, including the Targeted Agent Profiling and Utilization (TAPUR) clinical trial and projects to advance clinical trial design and methodology. CENTRA also staffs ASCO’s Cancer Research Committee and Research Community Forum.

Prior to joining ASCO, Suanna worked for seven and a half years in the U.S. House of Representatives, working for Congresswoman Nancy Johnson (R-CT) and Congressman Vernon Ehlers (R-MI). Ms. Bruinooge earned a Master’s of Public Health in Health Policy at The George Washington University’s Milken Institute School of Public Health in 2015. Suanna also has a B.A. in political science from Calvin College in Grand Rapids, MI.

Biosketches

Robert Carlson, MD

Robert W. Carlson, MD, is the Chief Executive Officer at the National Comprehensive Cancer Network (NCCN). He joined NCCN as CEO in January 2013 following an esteemed history of leadership positions within the organization including, most notably, Representative to the NCCN Board of Directors, Chair of the Breast Cancer Guidelines Panel, Member and Founding Chair of the Breast Cancer Risk Reduction Guidelines Panel, and the Chair of the Survivorship Guidelines Panel.

Prior to this appointment as CEO of NCCN, Dr. Carlson served as Professor of Medicine in the Division of Oncology and Stanford Medical Informatics at Stanford University Medical Center, as well as Medical Director of Inpatient oncology and hematology at Stanford Cancer Institute in California.

Dr. Carlson is a graduate of Stanford University Medical School, and he completed his internship and junior residency in Internal Medicine at Barnes Hospital Group in St. Louis before returning to Stanford University to complete his senior residency. He earned a Bachelor of Science with distinction from Stanford University, specializing in biological sciences. Dr. Carlson is board certified in Medical Oncology and Internal Medicine.

Joseph Chin, MD, MS

Joseph Chin, M.D., M.S., is the deputy director of the Coverage and Analysis Group (CAG) in the Center for Clinical Standards and Quality at the Centers for Medicare & Medicaid Services (CMS). He has served in his current role for the past 7 years overseeing transformative changes in Medicare coverage of innovative therapies and increasing patient access to new technologies. He joined CMS in 1992 as a senior

medical advisor in the quality improvement component and transitioned to CAG in 1999, focusing on systematic evidence reviews, Medicare translational science, and preventive services. Prior to joining CMS, Dr. Chin practiced full time in occupational and ambulatory medicine. He is board certified in preventive medicine. He completed his M.D., M.S. in epidemiology, and residency at the University of Maryland School of Medicine and maintained a primary care practice in Maryland for 26 years.

Dionne Christopher

Dionne S. Christopher, BA is a Program Manager, Cancer Screening & National Colorectal Cancer Roundtable for the American Cancer Society. In this role, she manages special projects that develop information resources which benefit the cancer community. Her work drive is to increase cancer screening rates and reduce the cancer mortality rates.

Prior to joining American Cancer Society in 2005, Dionne was the executive assistant at Bristol-Meyers Squibb, Pharmaceutical Company in the southeastern region for Abilify and Plavix medications. She has strong ties to family ties in the research and development of resources towards the elimination of cancer. Dionne currently serves as the president of a non-profit organization and serves on several advisory boards throughout metro Atlanta. Honed by years in conference planning, business and community service, she has the experience, skills, and drive to get things done, and has gained valuable experience in a full spectrum of issues affecting residents and business community. Dionne knows first-hand the issues that most interest College Park, its surrounding cities, needs of residents, families, youth, students, seniors and its businesses.

Biosketches

Ms. Christopher received her Bachelors degree from Saint Leo University in Atlanta, Georgia and will be obtaining her Masters in Public Health.

Terri Conneran

Terri Conneran is a three-time survivor of stage III non-small cell adenocarcinoma. Her involvement with LiveLung, and then the Go2 Foundation and LUNgevity, gave her the inspiration to found the Kras Kickers. It is the only network for patients and families in search of KRAS mutation information and support. Terri is a member of ASCO, IASLC, the Research Advocacy Network and the Society for Immunotherapy of Cancer. She shares her experience in many capacities, volunteering for NLCRT, the Lung Cancer Initiative of North Carolina, LungCAN, Go2 Foundation, LUNgevity and Novant Health.

Melissa Crouse

Melissa Crouse, a mother of three grown children and grandmother of six, was diagnosed with Stage IIA NSCLC Adenocarcinoma in August 2005. It was an accidental finding during a required physical. She had an upper left lobe lung resection followed by six rounds of chemotherapy. There wasn't any targeted therapy or extensive biomarker testing in 2005. Two and a half years later it was discovered that the cancer had metastasized to her liver. She's had multiple lines of chemotherapy, radiation, proton beam radiation and is on her sixth clinical trial. Currently, she is NED.

She retired from her teaching job in 2016 when her cancer progressed and she was enrolling in her sixth clinical trial. She established a local lung cancer support group and founded the RET Renegades. She's a patient consumer reviewer for the Department of Defense's CDMRP peer

review panel and sits on panels of several large pharmaceutical companies. She has appeared in numerous print and media, even earning an Emmy Award for a documentary featuring her.

Dusty Donaldson, MA

Dusty Donaldson is executive director of the Dusty Joy Foundation (LiveLung), a 501(c)(3) nonprofit with a focus of advancing lung cancer awareness, early detection and compassion for people impacted by lung cancer. Dusty co-authored the book "The ABCs of Lung Cancer for Patients and Advocates." She is co-chair of the Lung Cancer Action Network (LungCAN) and serves as a reviewer for lung cancer research proposals. She is a contributing writer for www.lungcancer.net and serves on the National Lung Cancer Roundtable's Survivorship, Stigma & Nihilism Task Group. Prior to being diagnosed with early-stage lung cancer in 2005, Dusty was a journalist and public relations professional with undergraduate and graduate degrees in journalism.

Kelly Durden, MA

Kelly Durden joined the American Cancer Society in 2011. During her tenure, she has served in several roles at both the regional and national levels, with her work spanning the cancer continuum, from early detection and screening to improving access to clinical trials. During her time in the Southeast Region, Kelly worked to create and lead the Georgia Lung Cancer Roundtable (GLCRT) and the Georgia Colorectal Cancer Roundtable (GCCRT). She presently manages the NFL Community Health Advocates implementing Nationwide Grants for Empowerment and Equity (CHANGE) lung-cancer funded projects, including the NFL CHANGE Lung Cancer Screening and Tobacco Cessation Pilot and the Bristol-Myers Squibb Foundation Health Centers Advancing Lung

Biosketches

Cancer Early Detection (BMSF-HALE) Pilot. Kelly also serves on the State-Based Initiatives Task Group of the National Lung Cancer Roundtable (NLCRT) and several workgroups in Georgia, including the Georgia Cancer Control Consortium (GC3), Staging and Treatment workgroup. Additionally, she supports several projects in the clinical trials portfolio of the ACS, including ACS CAN's Clinical Trial Barriers Implementation Workgroup.

Prior to joining the Society, Kelly served as the Program Manager at Family House in Pittsburgh, PA and as the Program Director for the Arthritis Foundation Western Pennsylvania Chapter. Kelly received her Master of Arts in Social and Public Policy with a concentration in Policy Analysis and Administration from Duquesne University. A native to Pittsburgh, Kelly is an avid Pittsburgh Steelers fan. She presently lives in Atlanta with her husband, an almost five-year old son, and two dachshunds.

George Eapen, MD

Dr. George Eapen is a Professor in the Department of Pulmonary Medicine at The University of Texas MD Anderson Cancer Center. His clinical interests are in the clinical management and care of patients with pulmonary manifestations and complications of cancer and cancer therapy. His academic career has been devoted to the care of the lung cancer patient where, as an interventional pulmonologist, he has focused on developing and integrating emerging advanced diagnostic and therapeutic techniques into cancer care. In an effort to improve the prognosis associated with a diagnosis of lung cancer, he focuses on early lung cancer detection, mediastinal staging, treatment and chemoprevention for those at risk. He has worked on many clinical trials over the course of his career and has extensive experience in close cross-discipline

collaboration. He has also had extensive experience maintaining a multi-disciplinary endobronchial ultrasound database that has had a significant impact on the management of patients with lung cancer and mesothelioma and have ongoing clinical trials evaluating endobronchial ultrasound as a minimally invasive tool for lung cancer diagnosis and mediastinal staging. He has experience in multi institutional collaboration as one of the early contributors to the American College of Chest Physicians AQUIRE registry., and actively participated and collaborated closely in field cancerization projects like the VANGUARD trial and biomarker driven projects like the BATTLE trial where bronchoscopic biopsies were used for sample acquisition. He has extensive experience in EBUS TBNA techniques, having performed over 3000 cases and have published our experiences in the diagnostic yield for lung cancer, granulomatous inflammation and lymphoma.

Lynne Elmore, PhD

Lynne Elmore, PhD, is the Scientific Director for Cell Biology and Preclinical Cancer Research in Extramural Discovery Sciences at the American Cancer Society. She manages a research portfolio that focuses on cancer cell growth, differentiation, and progression (including metastasis), experimental therapeutics, and biomarker discovery and development.

Dr. Elmore serves as the scientific liaison to the North Central and West Regions of the American Cancer Society, providing expert information, education and communication about cancer and American Cancer Society research programs to a variety of stakeholders. She is committed to leveraging internal and external partnerships to promote scientific advancement for the benefit of cancer patients

Biosketches

and to enhance training opportunities for cancer leaders of the future.

Prior to joining the American Cancer Society in 2017, Dr. Elmore was a faculty member in the Department of Pathology at Virginia Commonwealth University and a scientific member of Massey Cancer Center for over 18 years. Her independent research program focused on the role of epithelial-stromal interactions in cancer progression, with the hope of developing more effective targeted therapies.

Dr. Elmore graduated cum laude from Vanderbilt University with a bachelor's degree in Biology and from The Medical College of Virginia at Virginia Commonwealth University with a PhD in Pathology. She was a postdoctoral fellow in The Laboratory of Human Carcinogenesis at the National Cancer Institute.

Farhood Farjah, MD, MPH

Dr. Farhood Farjah is an Associate Professor of Surgery and Endowed Chair in Lung Cancer Research at the University of Washington. He is a member of the Multidisciplinary Thoracic Oncology Team at the Seattle Cancer Care Alliance. In his role as Associate Medical Director for the University of Washington Surgical Outcomes Research Center, Farhood helps train the next generation of surgeon-scientists. He is currently the Principal Investigator of a National Cancer Institute funded study of individuals with incidentally detected lung nodules that seeks to understand the relationship between the intensity of diagnostic evaluation and patient outcomes and healthcare costs. In addition to his work with the National Lung Cancer Roundtable, he serves on several committees for the Society of Thoracic Surgeons, American College of Chest Physicians, and the National Comprehensive Cancer Network. Farhood also serves on the

Editorial Board for CHEST, Annals of Thoracic Surgery, and the Journal of Thoracic and Cardiovascular Surgery.

Jill Feldman

Jill Feldman is a lung cancer patient and advocate. When Jill was 13 years old, she lost her dad and two grandparents to lung cancer and then her mom and close aunt died of lung cancer when she was in her 20's. She became a volunteer, an advocate and past president of LUNGevity Foundation before the unthinkable happened. In 2009, at 39 years old with four small children, Jill herself was diagnosed with EGFR positive lung cancer.

Jill continues to be involved with LUNGevity. She is also Deputy Chair of IASLC's patient advisory board and a member of The Chicago Institute of Translational Medicine's patient advisory board. Jill is committed to understanding and promoting patient-centered research as a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, as a planning committee member on IASLC's North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group's patient advocate committee and thoracic committee. Jill has presented patient perspectives at conferences, including the World Conference on Lung Cancer hosted by IASLC and the virtual ASCO Education Program. She is a co-author of the ASTRO Guidelines for SBRT in early stage lung cancer that was published in an ASCO special article in the Journal of Clinical Oncology.

In 2017, Jill co-founded the EGFR Resisters, a grassroots, patient-driven community committed to accelerating research that will prolong and better the lives of people diagnosed with EGFRm lung cancer. Jill also

Biosketches

continues to share her story in the media and at various events and participates in countless advocacy opportunities to shine a light on lung cancer and end the stigma associated with it.

Mark Fleury, PhD

Mark Fleury, PhD is a policy principal for the American Cancer Society Cancer Action Network (ACS CAN). He specializes in research, drug development, and regulatory policies along with other science and technology related projects. He has worked extensively on reform of diagnostic testing oversight, helped lead a coalition in 2016 that authored a landscape report on drug development challenges in pediatric cancer, and led another coalition in 2017 that created a report and recommendations focused on overcoming cancer clinical trial enrollment barriers. He currently sits on the steering committee of the Targeted Agent and Profiling Utilization Registry (TAPUR) Study, which examines the use of targeted anticancer agents used off-label in clinical settings. Throughout his work, Mark has striven to incorporate patient perspectives on to inherently science-based issues, advocating for the inclusion of patients as partners throughout the bench to bedside translation of science.

In addition to his ACS CAN experience, Mark's policy work includes time as a Capitol Hill legislative advisor focusing on healthcare reform, and work at the American Association for Cancer Research (AACR). He holds a PhD in bioengineering from the Ecole Polytechnique Federale de Lausanne in Switzerland, and conducted post-doctoral research at MIT. His former research includes investigating the mechanisms of tumor metastasis and the signaling pathways responsible for the activation of immune cells.

Janet Freeman-Daily, MS, Eng

Janet Freeman-Daily, MS, Eng, is a retired aerospace systems engineer (trained at MIT and Caltech), freelance writer, speaker, and metastatic lung cancer patient/activist. She was diagnosed with advanced non-small cell lung cancer in May 2011, and progressed to stage 4 despite two lines of chemo-radiation. Fortunately, she learned about biomarker testing and clinical trials from other patients in online lung cancer communities. Thanks to a targeted therapy clinical trial, she has had no sign of cancer on scans since January 2013. Her focus is now on translating the experience and science of cancer for others. She writes an [award-winning blog](#), cofounded and co-manages [The ROS1ders](#), serves on staff for the [IASLC STARS program](#), collaborates with lung cancer patient and advocacy organizations, and speaks as a research advocate at international oncology conferences, cancer research centers, biomedical and pharmaceutical companies, and government agencies. Her advocacy work focuses on ROS1 cancer, lung cancer, patient-centered outcomes, modernizing clinical trials, access to biomarker testing, data sharing, shared decision making, and goals of care.

Marianne Gandee, MA

Marianne joined Pfizer Oncology as the Senior Director of Advocacy & Professional Relations in the Fall of 2019. Prior to this role, she was the Director of Development and Strategic Alliances at the Association of Community Cancer Centers (ACCC). Marianne has a track record of building strong relationships with external and internal stakeholders and leads her team in

Biosketches

working with thought-leaders on a wide-range of oncology-focused advocacy and education initiatives. She brings over 20 years of experience at making connections to impact markets and motivate change.

During her time at ACCC, Marianne served as a primary liaison for ACCC's engagement with leaders from other professional medical societies, patient advocacy groups, healthcare organizations and pharmaceutical companies. She has been a trailblazer in creating unconventional partnerships and successfully engaging leaders to collaborate and execute on forward-thinking initiatives that helped address educational gaps of the multidisciplinary cancer care team and drive system change towards increasing access and optimal care for cancer patients.

She leads a strong team of seasoned advocacy professionals, across our core therapeutic areas, in creating meaningful collaborations and partnerships with advocacy and professional organizations. Her key areas of focus for 2020 include patient centricity, precision medicine and understanding overarching dynamics impacting care for patients in the U.S. Marianne and her team work diligently to keep the patient at the center of all we do as we create breakthroughs that change patients' lives. Marianne graduated cum laude with a BS in Psychology from the University of Mary Washington. She earned her Master's in Communication from Johns Hopkins University in 2011. She and her husband Jeff are both avid kiteboarders and live in Washington, DC.

Jill Hagenkord, MD

Dr. Hagenkord is a board-certified pathologist with subspecialty boards in molecular genetic pathology and an additional fellowship in pathology/oncology informatics. She trained at

Stanford (medical school), UCSF and University of Iowa (residency), and UPMC (fellowships). Jill was an Associate Professor of Pathology at Creighton University Medical School when she founded iKaryos, a cancer diagnostic company. She has subsequently served as the Chief Medical Officer of several Silicon Valley startups, such as Invitae, 23andMe, and Color. Jill is an active member in The Association for Molecular Pathology (AMP), The American College of Medical Genetics and Genomics (ACMG), The College of American Pathologists (CAP), and The National Academy of Medicine's Genomics and Precision Medicine Roundtable.

Karen Hamel

Karen is a director of patient advocacy at Novartis Oncology US. She manages the relationships with lung cancer patient groups, as well as with patient communities in other diseases including melanoma, neuroendocrine tumors and renal cell carcinoma, in the US. Karen has been at Novartis for 11 years and has previously been director of global patient relations, leading global patient advocacy strategy and engagement with different cancer and rare disease communities, and has been director of global and US brand communications for various oncology products. Karen has a deep background in patient advocacy and healthcare communications, working for many years as a consultant and at key public relations agencies prior to joining Novartis.

Amy Hanlon-Newall, PhD

Amy Hanlon Newell, PhD is the Global Medical Affairs Director for lung cancer, hematopathology, and PD-L1 (SP263) at Roche Tissue Diagnostics in Tucson, Arizona. Amy completed her undergraduate studies in biology at MIT and went on to earn her PhD from

Biosketches

Oregon Health & Science University in Molecular and Medical Genetics. In her doctoral studies, she studied Fanconi anemia, DNA repair, and cytogenetics. Amy's post-doctoral studies were at Portland VA Medical Center studying A-kinase Anchoring Proteins and their role in cilia and flagella movement. Following her post-doctoral fellowship, Amy led the OHSU/Knight Cancer Institute Research Cytogenetics Laboratory where she designed and implemented cytogenetic and FISH-based solutions to research problems, developing several biomarker assays for use in clinical trials of early lung cancer tyrosine kinase inhibitor therapies. Amy also taught Human Genetics and Cancer Genetics at OHSU Medical School. Amy joined industry in 2012 as Global Scientific Affairs Manager at Abbott Molecular and arrived at her current role at Roche in 2015.

Gina Hollenbeck, RN, BSN

Gina Hollenbeck is a Stage IV Lung Cancer survivor. She is a wife and mother of two boys. Gina is the President of ALK Positive, a patient-driven group dedicated to advancing research and awareness for ALK positive lung cancer. They have funded over \$1M in research grants for ALK Positive lung cancer. She is a driven advocate for lung cancer research, early detection, and biomarker testing.

Thomas Houston, MD

Dr. Houston is a graduate of the University of Mississippi School of Medicine. After a 10-year career in academic family medicine, he directed the American Medical Association's tobacco control and public health advocacy programs. From 2003 to 2005, he held the Jim Finks Chair in Health Promotion at LSU Health Sciences Center in New Orleans and was Professor of Public Health and Family Medicine. From 2005-2016, he worked at the McConnell Heart Health

Center in Columbus and directed tobacco cessation and policy initiatives for OhioHealth. He is currently Adjunct Professor in the Department of Family Medicine at The Ohio State University. He is past-president of the Ohio Academy of Family Physicians.

Sarah Hummasti, PhD

Sarah received her PhD in molecular biology from the University of California, Los Angeles after receiving her BA degree in biology from Reed College in Portland, OR. She went on to complete a post-doctoral fellowship at Harvard University in Boston, MA. In her more than 10 years of research experience, Sarah's work focused on the role of nuclear receptors, inflammatory signaling, and endoplasmic reticulum stress in obesity, diabetes, and other metabolic diseases.

For the past 8 years, Sarah has used her passion for translating science into easy-to-understand results by working closely with her pharmaceutical and biotechnology clients to create clear and concise scientific communications and strategies. Her work has included preparation of scientific manuscripts and reviews, advisory board materials and executive reports, and presentations for conferences and peer-to-peer speaker programs. She's often asked to analyze and interpret scientific data and literature in a broad range of therapeutic areas to understand how to put the current data into the context of the current treatment landscape and to highlight the impact to patient care.

As the Director, Scientific Content at AOIC, Sarah is responsible for ensuring the overall scientific integrity and editorial quality of the scientific content developed for our clients. She leads the medical writing team and reviews and oversees content development.

Biosketches

James Jett, MD

James Jett, M.D. has served as our Co-Chief Medical Officer since October 2019. Dr. Jett joined Biodesix after the acquisition of Oncimmune LLC where he served as Chief Medical Officer since 2016. Dr. Jett is a board-certified physician in Pulmonary Medicine and served in pulmonary medicine and on the consulting staff of Mayo Clinic in Rochester, Minnesota for 28 years before moving to join the faculty as a professor of medicine at National Jewish Health in Denver, Colorado from 2010 to 2015. His research interests have focused on screening, diagnosis, and treatment of lung cancer. From 2006 to 2012, Dr. Jett served as the Editor-in-Chief of the Journal of Thoracic Oncology and from 2008 to 2017 as the Co-Editor of the Lung Cancer Section of the premier medical electronic textbook Up-To-Date. Dr. Jett has held professional memberships with numerous organizations such as the American Thoracic Society, International Association for the Study of Lung Cancer, American Society of Clinical Oncology, North Central Cancer Treatment Group, and the American College of Chest Physicians. Dr. Jett received his doctorate degree from the University of Missouri in Columbia, Missouri and he completed his internal medicine and pulmonary medicine training at the Mayo Clinic. Dr. Jett's academic honors include the 2013 IASLC Merit Award, Clinical Educator Award from the ATS Assembly on Clinics Problems, 2014; selection for the 2015 Edition of Who's Who in America; and the Lifetime Achievement Award from the ATS Assembly on Thoracic Oncology, 2015.

Bruce Johnson, MD

Bruce E. Johnson, MD is the Chief Clinical Research Officer at Dana-Farber Cancer Institute, Institute Physician at Dana-Farber

Cancer Institute and Brigham and Women's Hospital, and Professor of Medicine at Harvard Medical School. His laboratory-based research is devoted to testing novel therapeutic agents for their efficacy against lung cancer and other thoracic malignancies.

Dr. Johnson is a member of the American Association of Physicians. He served on the American Society of Clinical Oncology (ASCO) Board of Directors from 2008-2011, received the ASCO Cancer Foundation's Translational Research Professorship in 2008, and was selected as a Fellow of the American Society of Clinical Oncology in 2012. Dr. Johnson will begin serving as ASCO President-Elect in June of 2016. He also was awarded the International Association for the Study of Lung Cancer (IASLC) 2010 Scientific Award, given to an IASLC scientist for "life-time scientific contribution in thoracic malignancy research and who has also contributed to the organization's development." He was one of the leaders of the team awarded the American Association for Cancer Research (AACR) 2010 Team Science Award that "recognizes an outstanding interdisciplinary research team for its innovative and meritorious science that has advanced or likely will advance our fundamental knowledge of cancer or a team that has applied existing knowledge to advance the detection, diagnosis, prevention, or treatment of cancer."

Dr. Johnson received his Doctor of Medicine from the University of Minnesota, did postgraduate training at the University of Chicago and the National Cancer Institute, and came to the Lowe Center in 1998 after serving for six years as the head of the Lung Cancer Biology section of the National Cancer Institute's Medicine Branch.

Biosketches

Ella Kazerooni, MD, MS

Ella A. Kazerooni, MD is a Professor of Radiology & Internal Medicine, and serves as the Associate Chief Clinical Officer for the Diagnostic and Clinical Information Oversight Team within the University of Michigan Medical Group (UMMG). She received her medical degree and completed her diagnostic radiology residency at University of Michigan in Ann Arbor, and fellowship at Massachusetts General Hospital/Harvard Medical School, joining the faculty at the University of Michigan in 1992.

She has served many roles in organized radiology, including president of the American Roentgen Ray Society, the Society of Thoracic Radiology, the Association of University Radiologist and the Radiology Alliance for Health Services Research in Radiology, a member of the American College of Radiology's Board of Chancellors and Executive Committee and Trustee of the American Board of Radiology. She is the inaugural chair of the American Cancer Society's Lung Cancer Roundtable, dedicated to creating lung cancer survivors through early detection and screening, improvements and access to modern diagnostics and treatments.

She is a frequently invited guest speaker at academic institutions and national/international meetings with expertise in lung cancer screening, and both interstitial and obstructive lung diseases is sought after by professional organizations developing multispecialty guidelines in radiology, pulmonary medicine and cardiovascular diseases with organizations such as the American College of Radiology (ACR), the American College of Cardiology Foundation and the National Quality Foundation. She currently is the Executive Sponsor of lung cancer screening activities of the ACR, where she also chairs the lung cancer screening registry and the Lung-RADS committee, and serves as the vice-chair of

the National Comprehensive Cancer Network Guideline on Lung Cancer Screening.

Edward Kim, MD

Edward S. Kim, MD is Chair of Solid Tumor Oncology and Investigational Therapeutics, Medical Director of the Clinical Trials Office, and the *Donald S. Kim* Distinguished Chair for Cancer Research at the Levine Cancer Institute, Atrium Health in Charlotte, NC.

Dr. Kim was previously at UT MD Anderson Cancer Center in Houston, Texas where he was a tenured Associate Professor of Medicine, Chief of the Section of Head and Neck Medical Oncology and Director of Clinical Research Operations in the Department of Thoracic/Head and Neck Medical Oncology.

Dr Kim received his Bachelor of Science and medical degrees from the Honors Program in Medical Education (HPME) at Northwestern University, his residency at Baylor College of Medicine, and his fellowship in medical oncology at UT MD Anderson Cancer Center.

Dr Kim specializes in cancer biomarkers and novel targeted agents in the treatment and prevention settings and has expertise in lung, head and neck cancers. He chaired the Department of Defense Biomarker-based Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) personalized medicine program in lung cancer. He currently oversees the solid tumor faculty and research development at Levine Cancer Institute.

Dr Kim is the author or coauthor of more than 100 published articles, book chapters, reviews in journals such as *Lancet*, *Lancet Oncology*, *Journal of Clinical Oncology*, *Cancer Discovery*, *Clinical Cancer Research*, *Cancer*, and *Cancer Prevention Research*, involving cancer

Biosketches

therapeutics and prevention with chemotherapy and novel targeted agents, with particular emphases on lung cancer and head and neck cancer.

Jennifer King, PhD

Jennifer C. King, PhD is the Chief Scientific Officer for GO₂ Foundation for Lung Cancer. She is a cancer research scientist turned patient advocate who offers a unique perspective; striking a balance between understanding the impact and mechanisms of new treatments and being able to explain what it all means to the greater cancer community. She uses her training to lead cutting-edge, research initiatives to improve the lives of those living with or at risk for lung cancer.

As a translational oncology researcher, Dr. King studied new molecular targets for cancer therapeutics and developed oncology mouse models while working at Memorial Sloan-Kettering Cancer Center and the Jonsson Comprehensive Cancer Center at UCLA. She has worked in the nonprofit space for over a decade, overseeing Conquer Cancer Foundation's research grant programs and portfolios, working in health IT and data governance for CancerLinQ, and co-founding a patient-facing health data sharing nonprofit, SHARE For Cures.

Dr. King serves on multiple advisory boards and workgroups for national organizations such as American Society of Clinical Oncology, the Agency for Healthcare Research and Quality, Association of Community Cancer Centers and the National Lung Cancer Roundtable as well as for pharmaceutical and diagnostics companies. She is a sought-after expert serving as the primary scientific spokesperson for GO₂ Foundation for Lung Cancer and has appeared in the *Chicago Tribune*, *Newsday*, *O - The Oprah*

Magazine, *CURE* and *The Lancet* addressing a wide range of cancer-related topics.

Dr. King received a PhD in Biology from the Massachusetts Institute of Technology and a BS from Duke University. She is a member of the American Association for Cancer Research, the American Society of Clinical Oncology, and the International Association for the Study of Lung Cancer.

Bryan Loy, MD, MBA

Bryan Loy MD, MBA is an industry recognized physician executive. He is a corporate medical director for Humana, a Fortune 100 health insurance company. Board certified in anatomic and clinical pathology and hematology, Dr. Loy currently leads Humana's cancer care strategy, including quality and value initiatives for laboratory, medical oncology and radiation oncology.

He has 19+ years of experience in evaluating drugs and biologics, medical devices, laboratory tests and innovations including both effectiveness and payment. He is well experienced in accelerating the appropriate adoption of new technology. He is an oncology and laboratory subject matter expert for pharmacy and therapeutics committees, policy development committees and completed his 3rd year as an advisor and co-chair for the Center for Medicare and Medicaid Services (CMS) advisory panel designed to evaluate appropriate payment for new complex lab tests. He works with the nation's most prominent commercial labs and oncology groups to implement cancer quality initiatives in all 50 states. He collaborates directly with industry-leading medical oncologists and practices committed to improving the patient experience.

A nationally recognized speaker, panelist, and author, Dr. Loy routinely presents on innovative cancer initiatives, the evolving landscape of

Biosketches

health care delivery and population health initiatives. He's helped 100000+ member employer groups understand medical cost and utilization and created strategies improving quality of care and value while improving the employee experience. He is co-chair for a large public-private partnership employing new population health technology combined with community collective impact initiatives to improve referral processes to agencies and resources that address social determinants of health.

In previous roles, he has served as a medical director for a multi-state Medicare contractor and as Chief Medical Officer for an innovative lab focused on tailoring treatment for breast and ovarian cancer patients.

Dr. Loy received his MBA (with distinction) from the University of Louisville and his MD from the University of Louisville. Dr. Loy continues to research and publish in population health, oncology, and molecular medicine.

Nikki Martin

Nikki Martin is Director of Precision Medicine Initiatives where she focuses on accelerating access to precision medicine for lung cancer patients. She is passionate about the need for members of the cancer community to work together to address common gaps in access to biomarker testing, and has been leading a multilateral coalition of 50 organizations to adopt consistent terms for testing in precision medicine in order to help eliminate patient confusion about the type of testing they need for their cancer. Prior to joining LUNGevery, Nikki worked in Alliance & Advocacy Relations at Genentech where she championed awareness of unmet needs and driving change in the patient community. Nikki held two roles at Grifols/Novartis Diagnostics in Global

Communications and also in Global Public Affairs. In those roles, she worked with global partners including sickle cell disease, hemophilia, and thalassemia patient advocacy groups, the Pan American Health Organization (PAHO), and the Asia Pacific Economic Cooperation (APEC) to educate the public, policy makers and other stakeholders on improving transfusion safety. She started her career in Japan where she worked at Cosmo PR advising healthcare clients on public relations activities in the Japanese market. She earned her MA in Commercial Diplomacy from the Monterey Institute of International Studies (now the Middlebury Institute of International Studies), and a BS in Anthropology and BA in Spanish from Santa Clara University. Nikki lives in Davis, CA with her wife and two dogs, Mia and Stuart.

Collette McCoy, MBA

Collette McCoy is AstraZeneca's US Lead for the Lung Ambition Alliance, a partnership focused on eliminating lung cancer as a cause of death, starting with goal of doubling the five year survival from lung cancer by 2025. Collette has over twenty years of pharmaceutical industry experience across multiple roles, including her most recent experience supporting innovative partnerships to address gaps in care with major oncology practices and institutions in southeastern parts of the US.

Collette also has a background in oncology patient advocacy, serving as one of the volunteer co-founders for the Lung Cancer Alliance's (now Go2 Foundation) work in Kentucky. While serving in this capacity she drove the establishment of lung cancer awareness and advocacy initiatives, including serving as an active participant in the Kentucky Cancer Consortium and as a community

Biosketches

advisory board member for the KY LEADS Collaborative.

Devon McGoldrick, MPH, CCPH

Devon McGoldrick, MPH, CCPH is part of the Advocacy & Professional Relations team at Lilly Oncology. Prior to joining Lilly, Devon enjoyed roles at the Livestrong Foundation, the National Cancer Institute and Memorial Sloan-Kettering Cancer Center. Devon holds a Bachelor of Science degree from Rochester Institute of Technology and is a Master of Public Health, with a focus area of Health Promotion/Disease Prevention from the Mailman School of Public Health at Columbia University. She is committed to improving experiences and outcomes for people affected by a cancer diagnosis.

Rhonda Meckstroth

Rhonda Meckstroth became a Lung Cancer Advocate when her spouse of 23 years, Jeff, was diagnosed in October 2015, during an annual physical/chest x-ray, with Stage 4 ALK Positive Lung Cancer. Jeff has no known risk factors but was a firefighter for 33 years and our rural home in Ohio was extremely high in radon. Rhonda is an Administrator/leader for the ALK Positive Patient Support Group and a 30 year government employee/administrative project specialist for the City of Piqua/Piqua Fire Department.

The main reason for advocacy is related to the medical challenges faced during her husband's diagnosis that coincide with administration of the large worldwide patient support site and reading similar challenges of others. The lack of public and medical information regarding NSCLC, biomarker testing, targeted therapies,

whole brain radiation and the expectation of the patient/caregiver to have to carry the burden of appropriate care is what drives her advocacy effort. She has working relationships with IASLC, Biden Cancer, American Cancer Society, NLCRT, LungCAN, Cancer Care, LUNgevity, GO2 Foundation, NCCN, Pfizer, Guardant Health, Foundation Medicine, Chris Draft Foundation, and other lung cancer groups, and initiated the ALK Positive organization to join the NLCRT in 2018, ALK Positive was the first patient support group to join and partner with NLCRT.

Kathryn Mileham, MD

Kathryn F. Mileham, MD, FACP has been with Atrium Health in hematology/oncology since completing her fellowship at Vanderbilt eleven years ago. She is currently Chief of the Section of Thoracic Medical Oncology and Associate Professor at Atrium Health's Levine Cancer Institute. She has been awarded Atrium Health's Provider of the Quarter and Patient Experience Top Care Provider as well as Charlotte Magazine's peer-selected Top Doctor for multiple years.

Dr. Mileham was selected for the 15th Workshop on Methods in Clinical Cancer Research. She is a graduate of the ASCO Leadership Development Program and is the current Chair of the ASCO Cancer Research Committee. She also serves on the Lung Cancer Initiative of North Carolina's Scientific Advisory Board. She is published in JCO, JAMA Oncology, and JOP and serves as the principal investigator for both sponsored and investigator-initiated protocols.

Biosketches

Amy Moore, PhD

As Director of Science and Research, Dr. Amy C. Moore combines her expertise as a Ph.D.-trained virologist and cancer researcher with over a decade of non-profit experience to help advance GO₂ Foundation's science initiatives, with a particular focus on cultivating partnerships and new research studies with our sister organization, the Addario Lung Cancer Medical Institute (ALCMI), as well as stewarding collaborations with patient groups and managing our grants portfolio. Before joining GO₂ Foundation, Amy spent 10 years building research capacity in the state of GA, where she served as the Director of Research Programs for the Georgia Research Alliance, a public:private partnership founded in 1990 that helped recruit leading scientists across GA's research universities and created startup companies around new technologies and discoveries emerging from university laboratories. She also previously served as Director of Research Programs for the Georgia Cancer Coalition, which leveraged GA's tobacco settlement dollars to build a nationally-recognized cancer initiative, with a focus on recruiting top researchers and launching a statewide biorepository. Amy earned her Ph.D. in Microbiology and Immunology from Wake Forest University School of Medicine and holds a B.S. in Biology (Phi Beta Kappa, *summa cum laude*) from Furman University. As a postdoc at Vanderbilt University Medical Center, she studied molecular mechanisms of acute leukemia development as an American Cancer Society Fellow. Amy also earned a professional certificate in Research Administration from Georgia State University, where she was in the first graduating class of the Executive Leadership Academy for Women and served as an adjunct faculty member in the Department of Biology and frequently taught a cancer course in the Honors College

Timothy Mullett, MD, MBA

Timothy Mullett, MD, is a Professor of Surgery in the Division of Cardiothoracic Surgery, Department of Surgery at the University of Kentucky. Since the projects inception in 2000, he has served on the Kentucky Lung Cancer Research Project (KLCRP) Governance Board, overseeing and directing the initiatives and funds of the KLCRP and serves as the Medical Director of the Kentucky Clinical Trials Network, an initiative of the KLCRP, which is a statewide network of sites conducting lung cancer trials. He serves as the Medical Director of the Markey Cancer Center Affiliate Network created to provide high-quality cancer care closer to home at collaborating centers, through specialty services, education and outreach programs. In addition, Dr. Mullett serves as the Medical Director of the Markey Cancer Center Research Network, a collaborative network of sites conducting a portfolio of high priority trials, including therapeutic oncology trials, interventional and non-interventional trials. He serves as Investigator and co-Investigator on numerous research grants funded by the Bristol Myers Squibb Foundation, and the Kentucky Lung Cancer Research Program. He also serves as co-Investigator of the Kentucky LEADS Collaborative, a portfolio of studies to reduce the burden of lung cancer in Kentucky through the development, evaluation and dissemination of novel, community-based interventions to promote clinician education, survivorship care and prevention and early detection of lung cancer. He serves as the co-chair of a LEADS Collaborative study, C3, to examine dissemination and implementation of lung cancer screening, an investigator-initiated trial of the Markey Cancer Center conducted throughout the state of Kentucky. His research interests also include a portfolio of studies on lung cancer screening, including shared decision making, serum biomarkers for lung cancer

Biosketches

screening, development and delivery of continuing medical education series for lung cancer screening programs, primary care and other healthcare practitioners on lung cancer screening

Dr. Mullett has been active with the Commission on Cancer for several years and was recently nominated and elected as the Chair-Elect for the CoC.

Jennifer Norton

Jen Norton leads Coverage & Pricing, Value Strategy & Marketing, and Contract Operations for the US Oncology and General Medicine commercial business units at Amgen.

Prior to joining Amgen Jen was most recently Vice President, Market Access & Reimbursement at Biogen, where she oversaw all US pricing and access functions for their Multiple Sclerosis and Spinal Muscular Atrophy programs, as well as market preparation activities for Alzheimer's therapies. Prior to Biogen, Jen was Senior Director of Pricing and Contract Administration at Vertex Pharmaceuticals, and Senior Director of Life Sciences Strategy at iMany.

Jen earned a BS in Business Administration from Northeastern University

Casey O'Neill

Casey O'Neill is an Oncology Strategy Principal at Genentech, a biotechnology company and member of the Roche Group based in South San Francisco, CA. He focuses on Genentech's personalized healthcare (PHC) strategy across the oncology portfolio including biomarker testing, digital health, and real-world data. Casey joined Genentech in 2016 and has functional experience across marketing, analytics, & access, as well as geographic

experience across the U.S. and Sub-Saharan Africa. Prior to joining Genentech, Casey's career spanned the public and nonprofit sectors with experience in the U.S. Senate, and at Harvard University's Institute of Politics. He earned his MBA from Vanderbilt University.

Carly Ornstein, MPH

Carly Ornstein joined the American Lung Association in 2012. Currently, she is the National Director of Lung Cancer Education for the American Lung Association. In that role, she manages and creates lung cancer educational content and support resources and provides guidance on the lung cancer patient experience for all of the Lung Association's lung cancer messaging and initiatives. She has conceived of and executed all of the Lung Association's educational biomarker campaigns. Carly has a Bachelor of Arts from the University of Maryland and a Masters of Public Health degree from George Washington University with a focus in health promotion. She is also a certified health education specialist.

Mary Pasquinelli, DNP, MSN

Mary Pasquinelli is currently a nurse practitioner specializing in lung cancer at the University of Illinois Hospital and Health Science System in Chicago (UI Health). She has over 30 years of oncology nursing experience. She holds a Master's degree of Science in Family Practice Nursing and a Doctorate in Nursing Practice. A major focus of her career has been focused on socioeconomically disadvantaged populations in Chicago. She established and oversees the UI Health's Lung Cancer Screening Program. Clinically she sees patients across the spectrum of lung neoplasms from those who are high risk for lung cancer, have pulmonary nodules, and patients on treatment for lung cancer. She prides herself in seeing lung malignancy

Biosketches

patients throughout the entire continuum of care, i.e., from lung cancer screening through diagnosis, treatment, and survivorship. Her research interests are in health disparities in lung cancer screening and in general thoracic oncology.

William Phelps, PhD

William (Bill) Phelps, PhD, worked in antiviral and anticancer research with the pharmaceutical industry for 13 years with GlaxoWellcome and GlaxoSmithKline. More recently, he spent 2½ years with a small startup biotech company as vice president of research and development before joining the American Cancer Society in 2004. Additionally, he held an appointment as adjunct professor of genetics and microbiology at Duke University Medical Center from 1996-2004, and completed a certification program from American University in change leadership.

Dr. Phelps graduated from Rhodes College in 1977 with a BS in Biology. He went on to graduate school first at Virginia Tech where he earned an MS in Botany and later, to the University of Minnesota earning his PhD in Microbiology in 1985. He was a postdoctoral fellow at the National Cancer Institute.

Suresh Ramalingam, MD

Suresh S. Ramalingam is Professor of Hematology and Medical Oncology and the Roberto C. Goizueta Chair for Cancer Research at the Emory University School of Medicine. He is also the Deputy Director of the Winship Cancer Institute of Emory University

Dr. Ramalingam's research is focused on the development of novel treatment approaches for patients with lung cancer. He has published more than 325 original manuscripts, review

articles, editorials and book chapters. He serves the principal investigator for the Emory University Lung Cancer SPORE award from the National Cancer Institute. He is also the contact principal investigator for the ECOG-ACRIN Thoracic Malignancies Translational Science Center Award from the National Cancer Institute.

Dr. Ramalingam serves as the Chair of the ECOG-ACRIN Thoracic Malignancies Committee. He is the section editor for 'Chest malignancies' for 'Cancer' journal. In addition, he serves on the editorial board for Annals of Oncology, Journal of the National Cancer Institute and Clinical Lung Cancer. Dr. Ramalingam is the recipient of several awards, including the James R. Eckman Award for Excellence at Emory University, and the Distinguished Cancer Scholar Award, Georgia Cancer Coalition. In addition, he is a recipient of the ASCO Career Development Award (2006–2009), the ECOG Young Investigator Award (2013), and the NCI Clinical Investigators Team Leadership Award (2010-12). Dr. Ramalingam serves as a member of the board of directors for the International Association for the Study of Lung Cancer (IASLC) and as a member of the NCI Thoracic Malignancies Steering Committee.

M. Patricia Rivera, MD

Dr. Rivera is a Professor of Medicine in the Pulmonary and Critical Care Medicine Division, Department of Medicine at the University of North Carolina at Chapel Hill in Chapel Hill, North Carolina.

Dr. Rivera joined the University of North Carolina at Chapel Hill faculty in 1995. She is Co-Director of the Multidisciplinary Thoracic Oncology Program, a Program that she co-founded in 1995, Director of the Lung Cancer Screening Program, and Director of the

Biosketches

Pulmonary Function and Bronchoscopy Laboratories.

Dr. Rivera received her M.D. from the State University of New York at Stony Brook in New York. She did her Internship and Residency in Internal Medicine at North Shore University Hospital in Manhasset, New York. She completed a Pulmonary Medicine/Critical Care Fellowship at Memorial Sloan-Kettering Cancer Center in New York, New York. Dr. Rivera has held numerous leadership positions including Chair of American Thoracic Society (ATS) Thoracic Oncology Assembly and Chair of the Thoracic Oncology Network of CHEST. In 2020 she was elected as Secretary-Treasurer of ATS and will serve as president of the organization in 2023 and selected as a member of the ABIM Pulmonary Exam Committee.

Dr. Rivera co-developed and serves as Co-Investigator of the North Carolina (NC) Lung Screening Registry. She collaborates with colleagues at UNC on several NIH/NCI funded grants to examine the delivery, quality and outcomes of lung cancer screening, the extent to which disparities in lung cancer screening outcomes exist, and the extent to which patient comorbidities and functional status impact lung cancer screening outcomes. She recently collaborated on a multi-institution pilot project exploring presence of coronary artery calcification on lung cancer screening CT and downstream risk stratification and statin delivery and exploring rural/urban disparities associated with biomarker testing in advanced lung cancer.

Dr. Rivera has received several honors and awards, including elected Secretary-Treasurer of the American Thoracic Society, the 2019 Assembly on Thoracic Oncology Lifetime Achievement Award, the 2019 Latin Medical Student Association Inaugural CHARLA Lecture

2019, the 2017 CHEST Presidential Honor Lecture, the 1998 University of North Carolina School of Medicine Whitehead Lecturer, the 2005 University of North Carolina White Coat Ceremony Keynote Speaker, and was nominated for the Humanitarian in Medicine award in 2004.

Al Rizzo, MD

Albert A. Rizzo, M.D., as Chief Medical Officer for the American Lung Association, is the organization's senior medical authority. Dr. Rizzo has long been a key medical advisor to the American Lung Association, a member of the Lung Cancer Expert Medical Advisory Panel and a leading media spokesperson for the Association. In his role as Chief Medical Officer, Dr. Rizzo plays a key role in multiple areas of our mission, including the American Lung Association's Lung HelpLine, research, including the Airways Clinical Research Centers and the Awards and Grants program as well as advocacy, communications, development and health promotions. Dr. Rizzo is responsible for ensuring that the American Lung Association is always using the best science and medicine to formulate and deliver on our mission. Additionally, Dr. Rizzo will help drive lung health innovation, challenge the Association to reach those in greatest need and strengthen our relationships with professional medical and patient organizations.

Dr. Rizzo is a member of Christiana Care Pulmonary Associates at the Christiana Care Health System in Newark, Delaware. He is board certified in internal medicine, pulmonary, critical care and sleep medicine and is a clinical assistant professor of medicine at Thomas Jefferson University Medical School in Philadelphia where he obtained his medical degree and completed his residency in internal medicine. Dr. Rizzo received his specialty

Biosketches

training at Georgetown University Hospital in Washington, D.C. He is a member of the American Thoracic Society, a Fellow of the American College of Chest Physicians and a Fellow of the American College of Physicians and a Diplomat of the American Board of Sleep Medicine and a Fellow of the American Association of Sleep Medicine.

His out-patient practice covers general pulmonary and sleep medicine disorders and includes a strong interest in asthma, COPD, pulmonary rehabilitation, lung cancer and obstructive sleep apnea.

Lauren Rosenthal, MPH

Lauren Rosenthal, MPH, is the Director of the National Lung Cancer Roundtable (NLCRT) at the American Cancer Society. She is responsible for directing long-term activities, developing strategic concepts, and overseeing the implementation of the NLCRT activities and initiatives, while creating and maintaining high-level collaborative partnerships with external partners and NLCRT member organizations.

Prior to joining the NLCRT, Lauren led the management of key regional and global health programs focusing on the American Cancer Society's global priorities and partnership initiatives, working closely with key policy stakeholders, funders, and cancer control partners internally and externally to promote women's cancer and non-communicable diseases programs. Lauren managed the ACS-founded Global Scholars Program, which allows high-achieving young professionals from Africa and India to hone their public health research, communications and advocacy skills with expert scientists, researchers, and advocates from ACS. Previously, Lauren was the Medical Affairs and Public Health Liaison from the Centers for Disease Control and Prevention, Center for

Chronic Disease Prevention and Health Promotion, to the Preventive Health Partnership, a collaboration among ACS, the American Diabetes Association, and the American Heart Association. The Partnership's aim was to stimulate substantial improvements in prevention and early detection of chronic diseases through greater public awareness about healthy lifestyles. In this role, Lauren managed the medical- and public health-related programs, communications, creation and promotion of health message materials, and relationships on a national platform.

Lauren holds a Master's degree in Public Health, with a concentration in epidemiology, from Emory University's Rollins School of Public Health and a Bachelor's degree in Biology from Kenyon College.

Kristen Santiago

Kristen Santiago has substantial experience working in the healthcare industry in roles in the public, private, and not-for-profit sectors. As Senior Director of Public Policy Initiatives for LUNgevity Foundation, Kristen is focused on breaking down barriers to patient access to high-quality care and treatment innovation. In her role, Kristen participates on a variety of committees and advisory boards to represent the interests and perspectives of lung cancer patients, presents at Capitol Hill briefings, submits letters to legislators, regulators, and independent organizations seeking patient input, and convenes multi-stakeholder meetings to resolve complex issues that hinder patient access to diagnostics and the most advanced therapeutics. Kristen's previous positions include: Senior Director, Policy & Advocacy for the Cancer Support Community; Director, Strategic Initiatives & Outreach for C-Change; as well as positions with TAP and Takeda Pharmaceuticals, The Commonwealth of

Biosketches

Pennsylvania, and the American Speech-Language-Hearing Association. Kristen earned a Masters of Science in Health Promotion Management at American University and a Bachelor of Arts in Speech Language Pathology from The George Washington University and is driven by a strong personal desire to impact the health status and quality of life of individuals through strategic alliance development and advocacy.

Gerard Silvestri, MD, MS

Gerard Silvestri, MD, MS is a lung cancer pulmonologist with a career dedicated to the evaluation, management and improvement of outcomes of patients with this most common of malignancies. He began the first multidisciplinary lung cancer clinic in South Carolina, and now evaluates between 5 and 7 new lung cancers per week. His research is patient oriented clinical research directed towards nearly every aspect of lung cancer care, including lung cancer screening, disparities in cancer care, shared decision-making and the evaluation and management of pulmonary nodules all of which are germane to screening for lung cancer. He has a graduate degree in the evaluative clinical sciences, and apply these health services research techniques to many aspects of lung cancer. He has developed a national and international reputation in lung cancer screening, having served on the DSMB of the national PLCO screening trial representing the lung arm of the trial. MUSC was a site for the National Lung Screening Trial and Dr. Silvestri served on the epidemiology working group after completion of the study. He served as a section editor and author of the American College of Chest Physicians evidence based guidelines on the diagnosis and management of lung cancer and have coauthored the chapter on screening, and his lab is interested in the generalizability of the findings of the NLST as

well as shared decision-making, disparities, risk stratification, and screen detected nodule evaluation and management. Dr. Silvestri participates as a Steering Committee member and Task Group Chair on the American Cancer Society's National Lung Cancer Screening Roundtable Steering Committee. To date, he has over 225 peer-reviewed journal publications, book chapters, and invited commentaries in clinical care and research of lung cancer.

Helmneh Sineshaw, PhD

Helmneh Sineshaw, MD, MPH, is a principal scientist at the American Cancer Society. His research has focused on examining patterns and outcomes of cancer treatments with respect to differences in determinants of health. The goal of his research is to uncover factors that influence access up-to-date high-quality care by understanding where, how much, for whom, and why care varies and generate evidence that will help to inform policy and practice, build more efficient and sustainable health care systems, and reduce disparities in cancer treatment and outcome across all population groups. He also collaborates with scientists from Massachusetts General Hospital, Harvard Medical School Dana-Farber Cancer Institute, Centers for Disease Control and Prevention, National Cancer Institute, North American Association of Central Cancer Registries, The University of Texas Medical Branch, Oregon Health Sciences University, Memphis Baptist Cancer Center, and others across the United States. Dr. Sineshaw received an MD degree from Addis Ababa University, Ethiopia and an MPH degree in Epidemiology from Indiana University-Purdue University.

Biosketches

Robert Smith, PhD

Dr. Robert A. Smith is a cancer epidemiologist and Senior Vice President and Director of the Center for Cancer Screening at the National Office of the American Cancer Society (ACS) in Atlanta, Georgia. He also is Adjunct Professor of Epidemiology at the Rollins School of Public Health, Emory University School of Medicine, and an Honorary Professor, Centre for Cancer Prevention, Wolfson Institute of Preventative Medicine at Queen Mary University of London. At the ACS he leads the development of cancer screening guidelines, and special research and policy projects focused on cancer prevention and control, including being Principal Investigator of the National Lung Cancer Roundtable. He received his PhD from the State University of New York at Stony Brook in 1983, and before joining the staff at the ACS, he held positions with the Boston University School of Public Health, and the CDC. He is the author of over 350 peer-reviewed scientific articles, reports, and book chapters, and a frequent lecturer on cancer screening issues. He serves on many international and national government and professional advisory committees, and in 2017 was a member of the International Agency for Research on Cancer (IARC) Handbooks Working Group on Colorectal Cancer Screening. Dr. Smith was one of the founding members of the National Colorectal Cancer Roundtable and has served as its Co-Director for 23 years. In 2011 he received the Medal of Honor from the International Agency for Research on Cancer.

Ryan Soisson

Ryan Soisson, founder of Soisson & Associates, is the Facilitator for the Biomarker Summit. He is committed to helping organizations, teams, and leaders achieve their most important goals in a sustainable manner. Ryan has considerable experience leading executive and management

groups through strategic planning, organization design, change management, project planning, and process improvement initiatives. Ryan has content expertise in a number of areas, including conflict resolution, coaching, and behavior change. As a certified team coach, Ryan specializes in team development and team interventions. Ryan has a passion for graphic facilitation, and enjoys integrating this skill into all his work.

Ryan holds an MA in Human Resources from Texas State University, and an MA in Philosophy from Texas A&M University and an undergraduate degree from Penn State University.

Patty Watkins

Patty Watkins was diagnosed with stage 4 metastatic lung cancer January, 2014 at age 57. She was in perfect health and not a smoker so this all came totally out of the blue. She walked 4 miles a day and participated in group classes 3 x week at the YMCA, (which she's able to do both walk and do her workout as always now). Talk about being totally blindsided. Statistics told her that her 5 year survival rate would be in the 1%. The doctors' prognosis was that she had just a few days to live. Today she is coming up on her 7th anniversary of being diagnosed in January 2019.

Patty uses her passion and story to press for more funding for research and new cutting edge targeted drugs to treat this insidious disease that claims more lives than any other cancer! Biomarker testing, research, clinical trials with new agents and early detection are all key to eradicating this #1 cancer killer!

Her dream is that every doctor tests their patients before they start to treat them so many will live and not be given just the off the

Biosketches

shelf chemotherapy that happens to @ 82% of patients.

Patty enjoys spending time with her family and new grandson as well as time walking trails by the river with friends (social distanced of course!) She got back to walking 4 miles a day after about a year of being in the hospital and recuperating and adjusting to her new 'normal'.

Her advocacy within many lung cancer groups is focused on early detection, biomarker testing and the NLCRT's Women and Lung Cancer & Biomarker task forces. Her advocacy also helped this National Lung Cancer Round Table during the Draft Foundation's Super Bowl Challenge or Lung Cancer Survivors in 2019, holding a pearls luncheon as well as an evening dinner with auction and band right before the Super Bowl, which had guest speakers including Winship Cancer Institute's esteemed research department. There were 325 people total in attendance and Patty raised many thousands of dollars for NLCRT.

Richard Wender, MD

Richard Wender MD has dedicated his career to leading medical and public health efforts that strive to improve the quality of primary care, implement population health, and address social determinants of health in the continuous pursuit of equity for all people. He was recently appointed as the Chair of the Department of Family Medicine and Community Health, in the Perelman School of Medicine at the University of Pennsylvania. Dr. Wender spent the first 33 years of his career in the Department of Family and Community Medicine at Thomas Jefferson University, including 12 years as the Alumni Professor and Chair of the Department. At Jefferson, Dr. Wender and his team spearheaded innovative programs in geriatric medicine, palliative care, the patient-centered

medical home, quality-based payment, refugee health, and community partnership. From 2013 to 2020, Dr. Wender served as the first Chief Cancer Control Officer of the American Cancer Society. He helped to build a cancer control team that launched a transformative national initiative to achieve 80% colorectal cancer screening rates in every community, a national and global campaign to increase HPV vaccination rates, and an enterprise-wide effort to help build healthier communities.

Dr. Wender has continuously advocated for the importance of preventive care and for the creation of an effective bridge between primary care and public health. This includes providing 100's of keynote addresses, at least one in all 50 states, and authoring numerous publications. As Chair of the National Colorectal Cancer Roundtable and a member of the steering committee for the President's Cancer Panel cancer screening initiative, Dr. Wender is helping to lead efforts to promote the safe provision of cancer screening services during the COVID-19 pandemic.

Dawn Wiatrek, PhD

Dawn E. Wiatrek, Ph.D. Strategic Director, Cancer Treatment Access American Cancer Society Dr. Wiatrek is the Strategic Director for Cancer Treatment Access for the American Cancer Society. In this role, she is responsible for the development and implementation of multi-level strategies and interventions to ensure equity in access to quality cancer care. She is currently serving as a consultant on a grant to engage FQHC's in lung cancer screening referral, where her focus is on supporting the tobacco cessation and shared decision components of the lung cancer screening referral process. Prior to this, she served as the National Director of the ACS Quitline Program, helping to shape the organization's overall strategy for tobacco control. She has served on

Biosketches

the advisory board of the North American Quitline Consortium, and has published several articles on tobacco cessation and control topics in peer reviewed scientific journals. She has extensive experience in the development and evaluation of evidence based psychosocial and behavioral interventions that focus on empowering patients to become more actively involved in the management of their own health and wellness. Dr. Wiatrek received her doctorate in Social Psychology/Behavioral Medicine with minors in Public Health and Quantitative Methods from the University of Houston and the University of Texas Health Science Center.

Ignacio Wistuba, MD

Dr. Wistuba is the Division Head ad interim in the Division of Pathology and Laboratory Medicine as well as Professor and Chair of the Department of Translational Molecular Pathology at The University of Texas MD Anderson Cancer Center. He serves as the Director of the Thoracic Molecular Pathology Laboratory, Director of The University of Texas Lung SPORE Tissue Bank, Director of the ECOG-ACRIN Central Biorepository and Pathology Facility (EA CBPF), Co-Director of the TMP-Immune-profiling Laboratory, Co-Director of the pre-CLIA Genomic Testing Developmental Laboratory, and Pathologist for the SWOG Lung Cancer Committee. One of his major research interests is the elucidation of the molecular abnormalities involved in the pathogenesis and progression of lung cancer. My research interests also include identifying new molecular targets, validating biomarkers for targeted therapy and immunotherapy (Lung Cancer Consortium trials), and identifying molecular markers (genomic intra-tumor heterogeneity, oncogenes activation, tumor microenvironment) associated with lung cancer tumor development, progression, and

metastasis development using annotated human specimens. In addition, he has established an invaluable tissue bank resource for thoracic malignancies at MD Anderson with more than 4,000 frozen and archival lung cancer and airway epithelia specimens from patients and a database of clinical, pathologic, and molecular information associated with these samples. Dr. Wistuba has co-authored over 600 peer-reviewed papers on oncology and is the PI or Co-PI on several molecular pathology and biomarker projects supported by multi-investigators and multi-institutional grants, and research agreements, including The University of Texas Lung Cancer NCI-SPORE grant, MD Anderson NCI-CCSG Tissue Bank and Pathology Resource, CPRIT Multi-Investigators Research Awards, and NCI-U24 grants to include ECOG-ACRIN CBPF and MD Anderson CIMAC.

Douglas Wood, MD

Dr. Douglas E. Wood is The Henry N. Harkins Professor and Chair of the Department of Surgery at University of Washington. Prior to that he was Professor and Endowed Chair in Lung Cancer Research in the Department of Surgery at the University of Washington, where he was the Chief of the Division of Cardiothoracic Surgery. Dr. Wood received his undergraduate and medical degrees from Harvard University and trained in General Surgery and Cardiothoracic Surgery at the Massachusetts General Hospital in Boston.

Dr. Wood is a world leader in thoracic surgery and thoracic oncology. He is past president of the Society of Thoracic Surgeons, Western Thoracic Surgical Association, Thoracic Surgery Foundation and Seattle Surgical Society, previously serving as Director of the American Board of Thoracic Surgery and Chair of the ACGME Thoracic RRC. Dr. Wood is currently the

Biosketches

president of the Cardiothoracic Surgery Network (CTSNet). He serves as the chair of the National Comprehensive Cancer Network (NCCN) Lung Cancer Screening Panel, vice chair of the NCCN Non-Small Cell Lung Cancer Panel, and vice chair of the National Lung Cancer Roundtable of the American Cancer Society.

Maureen Zakowski, MD, JD

Dr Zakowski is the Chief of Cytopathology and a Professor of Pathology at the Mount Sinai

Medical Center and School of Medicine in New York City. Her expertise is in Thoracic Pathology and Cytopathology, particularly in the early diagnosis of lung cancer and its molecular alterations. She was an attending pathologist at Memorial Sloan Kettering Cancer Center for more than 20 years before moving to Mount Sinai. She recently received a JD degree from Fordham University School of Law in New York City.